Definition
Lymphoid neoplastic manifestations of HIV infection include a spectrum of diseases each with specific clinical, epidemiologic, and biological features. This chapter reviews the important lymphoid tumors occurring in HIV infection with an emphasis on the important distinctions relevant to presentation, diagnosis, and clinical management of the various entities.
Introduction and Overview
During the late 1970s and early 1980s, marked changes in the typical occurrence and clinical behavior of aggressive B-cell lymphomas were among the initial manifestation of the new epidemic disease that ultimately became known as the acquired immunodeficiency syndrome, AIDS. The original Centers for Disease Control and Prevention case definition expanding the definition in 1982 of AIDS to include lymphoma specified that a patient with HIV and an aggressive B-cell lymphoma would carry an AIDS diagnosis. Several years later, this definition was expanded to include intermediate-grade B-cell...
This is a preview of subscription content, log in via an institution to check access.
References
Abayomi EA, Somers A, et al. Impact of the HIV epidemic and anti-retroviral treatment policy on lymphoma incidence and subtypes seen in the Western Cape of South Africa, 2002–2009: preliminary findings of the Tygerberg Lymphoma Study Group. Transfus Apher Sci. 2011;44(2):161–6.
Alizadeh AA, Eisen MB, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11.
Besson C, Goubar A, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001;98(8):2339–44.
Biggar RJ, Jaffe ES, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108(12):3786–91.
Breen E, Fatahi S, et al. Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin’s B cell lymphoma. Tumour Biol. 2006;27(4):187–94.
Castillo JJ, Beltran BE, et al. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2012;36(4):413–7.
Chadburn A, Chiu A, et al. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS malignancies consortium clinical trials 010 and 034. J Clin Oncol. 2009;27(30):5039–48. JCO.2008.2020.5450.
Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood. 2012;119(14):3245–55.
Dunleavy K, Little RF, et al. The role of tumor histogenesis, FDG-PET, and short course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017–24.
Fan W, Bubman D, et al. Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J Virol. 2005;79(2):1244–51.
Lindqvist M, van Lunzen J, et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest. 2012;122(9):3271–80.
Little RF, Pittaluga S, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101(12):4653–9.
Montoto S, Shaw K, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30(33):4111–6.
Raez L, Cabral L, et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses. 1999;15(8):713–9.
Rosenwald A, Wright G, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–47.
Sasakawa A, Hirase C, et al. Interleukin-8 in the pathogenesis of primary central nervous system lymphoma in association with HIV infection. Hematology. 2012;17(3):144–50.
Schmitz R, Young RM, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116–20. Advance online publication.
Shiels MS, Engels EA. Increased risk of histologically defined cancer subtypes in human immunodeficiency virus-infected individuals: clues for possible immunosuppression-related or infectious etiology. Cancer. 2012;118(19):4869–76.
Swerdlow SH, Campo E, et al. WHO classification of tumors of Haematopoietic and lymphoid tissues. Lyon: World Health Organization; 2008.
Uldrick TS, Polizzotto MN, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood. 2011;117(26):6977–86.
Wilson WH, Hernandez-Ilizaliturri FJ, et al. Novel disease targets and management approaches for diffuse large B-cell lymphoma. Leuk Lymphoma. 2010;51(S1):1–10.
Yang Y, Shaffer III AL, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21(6):723–37.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this entry
Cite this entry
Little, R.F., Pittaluga, S., Dunleavy, K. (2013). Presentation and Pathogenesis of B-Cell Lymphoid Cancers Associated with HIV Infection. In: Hope, T., Stevenson, M., Richman, D. (eds) Encyclopedia of AIDS. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9610-6_13-1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9610-6_13-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Online ISBN: 978-1-4614-9610-6
eBook Packages: Springer Reference MedicineReference Module Medicine